BAINBRIDGE, Ga. - Danimer Scientific, Inc. (NYSE: DNMR), a biotechnology company specializing in biomaterials, has received a $1.36 million award from the U.S. Department of Defense (DoD). The funding, provided through the Distributed Bioindustrial Manufacturing Program (DBIMP), is aimed at developing plans for a facility dedicated to producing biobased polyols for high-performance coatings used on ships, marine vessels, and steel piping.
The biobased coatings are touted to have superior properties compared to traditional petroleum-based options. If successful in the initial planning phase, Danimer may be eligible for a follow-on award, potentially granting access to up to $100 million for constructing a U.S.-based manufacturing facility.
This initiative is part of the White House's Executive Order 14081, which focuses on advancing biotechnology and biomanufacturing for a sustainable and secure American bioeconomy. The award is intended to strengthen the bioeconomic sector and support the DoD in achieving advanced defense capabilities.
Phil Van Trump, Danimer's Chief Science and Technology Officer, expressed enthusiasm for the funding, which will further the development of the company's innovative polyol biotechnology. He also highlighted the importance of supporting the DoD's efforts through the DBIMP and Executive Order 14081.
Danimer Scientific has been at the forefront of creating more sustainable plastic products for over two decades. Their biopolymers are used in a variety of applications, including fibers, films, and injection-molded articles, and are known for being biodegradable and compostable.
The DBIMP, under the Defense Industrial Base Consortium (DIBC) Other Transaction Agreement (OTA), supports businesses in producing plans for domestic bioindustrial manufacturing production facilities. These efforts are part of a broader push to increase the domestic supply of critical materials for defense.
The information in this article is based on a press release statement from Danimer Scientific. The company holds over 480 granted patents and pending patent applications in more than 20 countries, covering a wide range of manufacturing processes and biopolymer formulations. Danimer's role in this initiative marks a significant step in the U.S. government's investment in sustainable manufacturing and defense readiness.
In other recent news, Danimer Scientific has seen significant changes in its financial landscape. The company's stock rating was recently downgraded from Buy to Hold by TD Cowen, with the price target also reduced to $1. This adjustment follows slower than expected growth at the company's Kentucky facility, as noted by the firm. In a parallel development, Jefferies also downgraded the company's stock from Buy to Hold, adjusting the price target to $0.80 following the announcement of a CEO transition.
In addition to these rating changes, the company has made notable strides in its corporate structure. Danimer Scientific's stockholders approved an amendment to its Articles of Incorporation, increasing the authorized shares of Class A common stock from 200 million to 600 million. This move could potentially provide the company with increased flexibility for future corporate needs.
Despite facing a gross loss, Danimer Scientific reported a significant increase in PHA revenues in the first quarter of 2024. The company's ongoing commercialization efforts and R&D trials are expected to contribute to future revenue growth. Amid these developments, the company also confirmed a CEO transition, with Stephen E. Croskrey planning to retire by the end of 2024. An executive committee has been established to oversee the search for Croskrey's successor. These are the recent developments concerning Danimer Scientific.
InvestingPro Insights
Amidst its collaboration with the U.S. Department of Defense, Danimer Scientific, Inc. (NYSE: DNMR) is navigating the challenges of a competitive biotechnology market. According to real-time data from InvestingPro, Danimer's market capitalization stands at a modest $44.69 million. This reflects the company's current valuation in the context of its financial performance and market conditions.
InvestingPro data also highlights the company's Price / Book ratio for the last twelve months as of Q2 2024, which is at 0.19. This low multiple suggests that the stock may be undervalued relative to the company's book value, potentially presenting an opportunity for investors seeking assets at a price less than their intrinsic value. Additionally, Danimer's revenue for the same period was reported at $39.74 million, although it experienced a significant decline of 21.4% in revenue growth.
Two notable InvestingPro Tips for Danimer Scientific include analysts revising their earnings upwards for the upcoming period, indicating potential optimism about the company's future financial performance. On the other hand, the company is noted to be quickly burning through cash, which could be a concern for its operational sustainability and long-term growth. For investors and stakeholders, these insights may be critical in assessing the company's financial health and investment potential.
For those interested in a deeper analysis, InvestingPro offers additional tips on Danimer Scientific, which can be found at https://www.investing.com/pro/DNMR. The platform provides a comprehensive view of the company's financial metrics and analyst forecasts, aiding in making more informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.